Zoetis VMRD, 333 Portage Street, Kalamazoo, MI, 49007, USA.
Zoetis Belgium SA, Rue Laid Burniat 1, 1348, Louvain-La-Neuve, Belgium.
BMC Vet Res. 2022 Mar 17;18(1):103. doi: 10.1186/s12917-022-03210-x.
The oral acceptance of oclacitinib maleate (Apoquel®) chewable tablets administered twice daily for 7 days at the labeled dose range of 0.4-0.6 mg/kg was evaluated in 121 dogs treated at ten general practice veterinary clinics in the United States.
Dogs that were enrolled in the study were client-owned, ranged from 1 to 14 years of age, weighed 3.7 to 60.7 kg, and required twice daily treatment with Apoquel for allergic or atopic dermatitis for 7 days. One hundred and twenty-one (121) dogs with 1673 total dose administrations successfully completed the study and were included in the data summary. Out of a total number of 1673 administrations, 1533 (91.6%) were accepted voluntarily within 5 min, 134 (8%) were consumed with assistance (with food treats or by pilling) outside of the 5 min offering time and 6 (0.4%) doses were not consumed. The per dose percent acceptance rate for the 14 offered doses showed minimal variation ranging from 89.9 to 93.3%.
Client-owned dogs from the general veterinary patient population that required treatment with oclacitinib found the chewable tablets to be very palatable and no aversion occurred with repeated dosing. Oclacitinib chewable tablets were well tolerated and are a palatable alternative to the film-coated tablet.
在十家美国普通兽医诊所中，对 121 只接受为期 7 天、每天两次、标签剂量范围为 0.4-0.6mg/kg 的马来酸奥卡西平（Apoquel®）可咀嚼片剂口服的犬进行了评估。
研究中纳入的犬均为客户所有，年龄 1-14 岁，体重 3.7-60.7kg，需要每天两次用 Apoquel 治疗过敏或特应性皮炎，持续 7 天。121 只犬共进行了 1673 次给药，成功完成了研究，纳入数据总结。在总共 1673 次给药中，有 1533 次（91.6%）在 5 分钟内自愿接受，134 次（8%）在 5 分钟给药时间之外通过食物奖励或喂药器协助摄入，6 次（0.4%）未被摄入。在提供的 14 个剂量中，每个剂量的接受率变化极小，范围在 89.9%至 93.3%之间。
需要用奥卡西平治疗的普通兽医患者群体中的客户所有犬认为可咀嚼片剂非常可口，并且重复给药不会产生厌恶。奥卡西平可咀嚼片剂耐受性良好，是薄膜包衣片剂的可口替代品。
